Skip to main content

Advertisement

Table 3 Absolute overestimation (%) in cumulative recrudescence estimates using K–M analysis compared to Cumulative Incidence Function

From: Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis

  N Absolute overestimationa Observed proportion of recrudescenceb Observed proportion of competing risk eventsb
Day 28
 AL 88 0.02% [IQR: 0.00–0.12%; Range: 0.00–2.54%] 2.1% [0.1–16.0%] 9.8% [0.0–51.4%]
 ASAQ 21 0.03% [IQR: 0.00–0.10%; Range: 0.00–0.98%] 2.5% [0.3–12.8%] 10.2% [0.0–45.4%]
 ASMQ 8 0.00% [IQR: 0.00–0.03%; Range: 0.00–0.08%] 1.9% [0.8–7.0%] 11.0% [6.3–14.0%]
DP 30 0.00% [IQR: 0.00–0.00%; Range: 0.00–0.16%] 1.3% [0.4–16.4%] 2.7% [0.0–36.8%]
Day 42
 AL 48 0.25% [IQR: 0.03–0.65%; Range: 0.00–3.24%] 3.7% [0.6–18.0%] 21.6% [0.0–65.4%]
 ASAQ 9 0.23% [IQR: 0.02–0.69%; Range: 0.00–2.24%] 3.3% [1.0–17.0%] 18.4% [2.3–65.2%]
 ASMQ 8 0.25% [IQR: 0.12–0.50%; Range: 0.00–1.03%] 3.7% [1.4–11.3%] 25.3% [1.0–43.3%]
 DP 21 0.00% [IQR: 0.00–0.19%; Range: 0.00–0.73%] 1.9% [0.8–16.4%] 7.1% [0.0–34.6%]
Day 63
 AL 9 0.96% [IQR: 0.65–1.38%; Range: 0.012–3.42%] 3.7% [1.4–10.6%] 7.1% [0.0–34.6%]
 ASAQ 2 0.18% [IQR: 0.09–0.27%; Range: 0.00–0.36%] 12.3% 18.5%
 ASMQ 7 0.98% [IQR: 0.38–2.20%; Range: 0.21–3.59%] 4.1% [1.6–12.7%] 4.1% [1.6–12.7%]
 DP 8 0.14% [IQR: 0.01–0.38%; Range: 0.00–0.89%] 2.2% [1.6–12.7%] 7.1% [3.4–30.0%]
  1. N number of study sites with study sample size ≥ 25, AL artemether–lumefantrine, ASAQ artesunate–amodaiquine, DP dihydroartemisinin–piperaquine, ASMQ artesunate–mefloquine, IQR interquartile range
  2. aValues are median [Interquartile Range (IQR); Range] for \(\hat{F}_{KM} \left( t \right) - \hat{F}_{CIF} \left( t \right)\)
  3. bValues are median [Range]